For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
In the latest session, Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) closed at $27.82 down -3.27% from its previous closing price of $28.76. In other words, the price has decreased by -$3.27 from its previous closing price. On the day, 1.61 million shares were traded. RARE stock price reached its highest trading level at $28.7 during the session, while it also had its lowest trading level at $27.75.
Ratios:
For a deeper understanding of Ultragenyx Pharmaceutical Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.30 and its Current Ratio is at 2.45. In the meantime, Its Debt-to-Equity ratio is 5.84 whereas as Long-Term Debt/Eq ratio is at 5.34.
Goldman Upgraded its Neutral to Buy on June 06, 2024, whereas the target price for the stock was revised from $56 to $67.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Sep 18 ’25 when Huizenga Theodore Alan sold 64 shares for $29.17 per share. The transaction valued at 1,867 led to the insider holds 50,242 shares of the business.
KARAH PARSCHAUER bought 2,450 shares of RARE for $76,366 on Sep 12 ’25. On Sep 12 ’25, another insider, Parschauer Karah Herdman, who serves as the EVP and Chief Legal Officer of the company, sold 2,450 shares for $31.17 each. As a result, the insider received 76,366 and left with 73,271 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RARE now has a Market Capitalization of 2681059072 and an Enterprise Value of 3078568192. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.39 while its Price-to-Book (P/B) ratio in mrq is 17.69. Its current Enterprise Value per Revenue stands at 5.046 whereas that against EBITDA is -6.555.
Stock Price History:
The Beta on a monthly basis for RARE is 0.20, which has changed by -0.4888848 over the last 52 weeks, in comparison to a change of 0.15101504 over the same period for the S&P500. Over the past 52 weeks, RARE has reached a high of $57.99, while it has fallen to a 52-week low of $25.81. The 50-Day Moving Average of the stock is -4.03%, while the 200-Day Moving Average is calculated to be -24.10%.
Shares Statistics:
For the past three months, RARE has traded an average of 2.07M shares per day and 1847210 over the past ten days. A total of 96.18M shares are outstanding, with a floating share count of 89.64M. Insiders hold about 6.99% of the company’s shares, while institutions hold 97.65% stake in the company. Shares short for RARE as of 1757894400 were 7947955 with a Short Ratio of 3.84, compared to 1755216000 on 8405280. Therefore, it implies a Short% of Shares Outstanding of 7947955 and a Short% of Float of 8.540000000000001.
Earnings Estimates
The current rating of Ultragenyx Pharmaceutical Inc (RARE) is the result of assessments by 12.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is -$1.11, with high estimates of -$0.8 and low estimates of -$1.54.
Analysts are recommending an EPS of between -$4.48 and -$5.66 for the fiscal current year, implying an average EPS of -$5.06. EPS for the following year is -$3.71, with 12.0 analysts recommending between -$1.06 and -$5.57.
Revenue Estimates
A total of 15 analysts believe the company’s revenue will be $167.42M this quarter.It ranges from a high estimate of $175M to a low estimate of $158M. As of the current estimate, Ultragenyx Pharmaceutical Inc’s year-ago sales were $139.49MFor the next quarter, 15 analysts are estimating revenue of $183.42M. There is a high estimate of $193.92M for the next quarter, whereas the lowest estimate is $172.07M.
A total of 19 analysts have provided revenue estimates for RARE’s current fiscal year. The highest revenue estimate was $668.55M, while the lowest revenue estimate was $641.7M, resulting in an average revenue estimate of $657.76M. In the same quarter a year ago, actual revenue was $560.23MBased on 19 analysts’ estimates, the company’s revenue will be $806.24M in the next fiscal year. The high estimate is $1.03B and the low estimate is $673.2M.
